1
Return

Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma

delete2018-01-01
delete57
delete
OA
AI
D
de la Puente, Pilar
L
Luderer, Micah J.
C
Cinzia Federico
A
Abbey Jin
R
Rebecca C. Gilson
E
Egbulefu, Christopher
K
Kinan Alhallak
S
Shah, Shruti
M
Muz, Barbara
J
Jennifer Sun
J
Justin King
K
Kohnen, Daniel
N
Noha N. Salama
S
Samuel Achilefu
V
Vij, Ravi
A
Azab, Abdel Kareem *
DOI:10.1016/j.jconrel.2017.11.045delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
The establishment of more effective treatments that can circumvent chemoresistance in Multiple Myeloma (MM) is a priority. Although bortezomib (BTZ) is one of the most potent proteasome inhibitors available, still possesses limitations related to dose limiting side effects. Several strategies have been developed to improve the delivery of chemotherapies to MM by targeting different moieties expressed on MM cells to nanoparticle delivery systems (NPs), which have failed mainly due to their heterogeneous expression on these cells. Our goal was to test CD38 targeted chitosan NPs as novel targeting moiety for MM to improve the potency and efficacy of BTZ in MM cells and reduce the side effects in healthy tissue. We have showed preferential BTZ release in tumor-micro-environment, specific binding to MM cells, and an improved drug cellular uptake through BTZ diffusion from the surface and endocytosed NPs, which translated in enhanced proteasome inhibition and robust cytotoxic effect on MM cells when BTZ was administered through anti-CD38 chitosan NPs. Furthermore, the anti-CD38 chitosan NPs specifically delivered therapeutic agents to MM cells improving therapeutic efficacy and reducing side effects in vivo. The anti-CD38 chitosan NPs showed low toxicity profile allowing enhancement of proteasome-inhibitory activity and specificity of BTZ by endocytosis-mediated uptake of CD38 representing a promising therapy in MM.
Keywords:
CD38
Bortezomib
Endocytosis
Nanoparticles, multiple myeloma
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

Journal of Controlled Release cover
Journal of Controlled Release
IF:
11.5
Papers:
1.5W
Citations:
7.4W

Organization

E
egyptian knowledge bank (ekb)
Scholars:
11.3W
Papers: 9.1W
Citations: 84
W
washington university (wustl)
Scholars:
5.4W
Papers: 4.5W
Citations: 68
C
Cairo University
Scholars:
1.3W
Papers: 1.0W
Citations: 1.7W
Cited Papers

Cited Papers

Citing Papers

Citing Papers